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Abstract
The gut microbiome plays a significant role in health and disease, and there is mounting evidence indicating that the microbial 
composition is regulated in part by host genetics. Heritability estimates for microbial abundance in mice and humans range 
from (0.05–0.45), indicating that 5–45% of inter-individual variation can be explained by genetics. Through twin studies, 
genetic association studies, systems genetics, and genome-wide association studies (GWAS), hundreds of specific host 
genetic loci have been shown to associate with the abundance of discrete gut microbes. Using genetically engineered knock-
out mice, at least 30 specific genes have now been validated as having specific effects on the microbiome. The relationships 
among of host genetics, microbiome composition, and abundance, and disease is now beginning to be unraveled through 
experiments designed to test causality. The genetic control of disease and its relationship to the microbiome can manifest 
in multiple ways. First, a genetic variant may directly cause the disease phenotype, resulting in an altered microbiome as a 
consequence of the disease phenotype. Second, a genetic variant may alter gene expression in the host, which in turn alters 
the microbiome, producing the disease phenotype. Finally, the genetic variant may alter the microbiome directly, which 
can result in the disease phenotype. In order to understand the processes that underlie the onset and progression of certain 
diseases, future research must take into account the relationship among host genetics, microbiome, and disease phenotype, 
and the resources needed to study these relationships.
Host genetic control of the microbiome 
impacts health and disease
Candidate genes and genome-wide association studies 
(GWAS) have yielded significant insight into the genetic 
variations influencing health and disease. Due in large part 
to advances in next generation, high-throughput sequenc-
ing, and proteomics platforms, the number of reports on the 
contribution of the gut microbiome to certain diseases has 
escalated in recent years. The human gut contains  1013–1014 
bacteria from thousands of species, and their collective 
genomes contain > 150 times more genes than the human or 
mouse genome (Backhed et al. 2005; Gill et al. 2006; Sender 
et al. 2016). These bacteria (and viruses, fungi, etc.) are col-
lectively termed the gut microbiome, and their gene content 
(the metagenome) is often called our second genome (Grice 
and Segre 2012). Like the host genome, the gut microbi-
ome composition and diversity in each individual are unique 
(Huse et al. 2012; Zhou et al. 2013).
There is growing awareness in the medical commu-
nity that an imbalance of the gut microbiome (dysbiosis) 
is associated with various local and systemic diseases 
(Shreiner et al. 2015). Dysbiosis has become a hallmark 
of many diseases, often seen as a symptom of the disease, 
but not generally considered in the pathogenesis of the 
disease (Wilkins et al. 2019). Studies using fecal micro-
biome transplantation (FMT) between obese and lean 
mice (Turnbaugh et al. 2008) and between lean and obese 
human donors into mice (Ridaura et al. 2013) indicated 
that the donor phenotype was transferred to the recipient 
by the microbiome, demonstrating that the remarkable role 
commensals play in modulating host phenotype. Since the 
largest pool of microbes exists in the distal gastrointesti-
nal tract, dysbiosis of the gut microbiome is most readily 
associated with region-specific gastrointestinal diseases 
such as Crohn’s disease, inflammatory bowel disease 
(IBD), irritable bowel syndrome (IBS), colorectal cancer, 
and celiac disease (reviewed in (Gorkiewicz and Moschen 
2018)). More recently, attention has turned to the role of 
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the gut microbiome in behavioral and neurological condi-
tions. FMT from a healthy donor to an afflicted patient 
has been reported to mitigate disease severity in individu-
als with autism spectrum disorder (Yang et al. 2020) and 
multiple sclerosis (Engen et al. 2020; Schepici et al. 2019). 
Other neurological conditions such as Parkinson’s disease 
(Sampson et al. 2016) and depression (Zheng et al. 2016) 
have also shown a microbiome-dependent component. 
Together, these studies demonstrate that the gut microbi-
ome can influence the pathogenesis of not only gastrointes-
tinal diseases, but also behavioral and neurological condi-
tions, likely involving microbial metabolites that function 
along the gut-brain axis (Cryan et al. 2019).
FMT has become the standard of care for recurrent 
Clostridium difficile infections (Brandt 2012; Wilcox et al. 
2020). The clinical benefits of such treatment are only real-
ized if there is successful colonization of donor microbi-
ota in the new host. Some FMT treatments only result in a 
transient repopulation and may need to be repeated. This 
transient colonization may be due to host genetic factors 
preventing successful engraftment. Understanding the host 
genetic factors that influence microbial engraftment is, thus, 
essential to establish more practical and cost-effective trans-
plant therapies. Furthermore, the development of therapies 
that are not dependent on the microbe itself but rather the 
small-molecule metabolites made by the microbe would be 
applicable to all hosts.
Host genetics associated with microbiome 
composition in humans
Analysis of sequencing data of the human genome com-
pleted in 2003 (International Human Genome Sequencing 
2004) and the human microbiome in 2016 revealed an asso-
ciation of various diseases with both our human genome 
and our gut commensals (Human Microbiome Project 2012). 
These efforts, combined with international programs such 
as the Metagenomics of the Human Intestinal Tract project 
(Lee-Sarwar et al. 2020), have provided insight into the cru-
cial host–microbe interactions that function in health and 
disease. These projects have also contributed numerous 
bioinformatics tools and reference databases, enhancing our 
understanding of the specific function of the microbiome in 
the pathoetiology of disease.
As outlined in Fig. 1, much has been learned from the 
human genome as to how a host genetic variant may result in 
an altered phenotype. The variant may directly (Pathway I) 
or indirectly (through alterations in the expression of down-
stream genes for example, Pathway II) modulate a pheno-
type. The altered phenotype from these two pathways could 
Fig. 1  Model representing possible direct and indirect pathways by 
which the gut microbiome and host genetics control phenotype. I. 
Individuals with certain gene variants (indicated by red dot) are sus-
ceptible to development of an altered phenotype. II. The gene vari-
ant modulates the expression of downstream genes and subsequently 
affects a phenotype, which can alter the microbiome. III. Host genes 
determine the gut microbiome composition directly. The gut micro-
biome (IIIa) and their products (such as short-chain fatty acids) can 
directly modulate the phenotype (IIIc), and/or indirectly affect the 
phenotype by affecting host gene expression (IIIb). External factors 
(IV) such as diet or drugs can alter the gut microbiome, leading to a 
microbiome driven
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in turn circle back and modulate the microbiome. Finally, a 
host genetic variant may directly impact the gut microbiome 
(Pathway III) which in turn may result in an altered host phe-
notype either directly through their cell surface molecules 
(Pathway IIIa), metabolites such as short-chain fatty acids 
(Pathway IIIc) or indirectly through subsequent effects on 
host genes (Pathway IIIb).
FMT is the preferred approach for defining cause and 
effect, but has inherent limitations. Transplantation of 
numerous recipient mice with the samples from a single 
human with a specific disease (and a single human con-
trol) are underpowered as they represent an n = 1 approach 
(Walter et al. 2020). Further, many studies pool donor sam-
ples resulting in an inability to determine what microbiome 
composition was responsible for the phenotype. Finally, 
multiple studies fail to verify engraftment, so it is uncertain 
if failure to alter a phenotype is the true outcome or due 
to engraftment failure. Future experiments are encouraged 
to increase rigor to address causality by not pooling donor 
samples, verifying engraftment of the differential microbi-
omes (determining if the animals are dysbiotic) and taking 
other conservative measures to avoid the overstatement of a 
study’s conclusions (Walter et al. 2020).
The role for the microbiome in host phenotypes is very 
relevant for discovering genotype–phenotype relations such 
as in GWAS or other human genetic approaches. The vast 
majority of this work does not include microbiome analy-
sis and, thus, assumes the mechanisms of Pathways I or II 
in Fig. 1. A phenotype mediated through the microbiome 
(Pathway III) presents a different mechanism and, thus, has 
different approaches to diagnosis and therapy when it is 
disease related. Moreover, since there is variability in the 
microbiome between subjects, this can manifest as pheno-
typic variation, lower penetrance, or other effects that influ-
ence human genetic analysis and its use in the clinic. Deeper 
understanding of microbiome–host genetic relationships is, 
thus, crucial for medical applications.
A subset of diseases exists for which the genetics of the 
host determine the microbiome. The most well-studied 
example is the disorder familial Mediterranean fever (FMF), 
a genetic autoinflammatory disorder that causes recurrent 
fevers and painful inflammation in the abdomen, lungs, and 
joints. FMF is linked to a mutation in the human MEFV 
(Mediterranean fever) gene, which encodes the pyrin pro-
tein, a regulator of the innate immune system (Di Ciaula 
et al. 2020). MEFV, through its innate immune function, 
also controls the gut microbiome composition (Di Ciaula 
et al. 2020). During times of active FMF, the gut microbi-
ome exhibits a depletion of total numbers of bacteria, loss of 
diversity, and shifts in relative abundance of populations of 
Bacteroidetes, Firmicutes, and Proteobacteria phyla (Kha-
chatryan et al. 2008). As the change in microbiome compo-
sition occurs during time of active disease symptoms, the 
pathway of control would be a direct route where the genetic 
variant impacts the phenotype (i.e., causes MEFV), which 
results in a subsequent altered microbiome.
Microbiome composition is a complex heritable trait
Heritability is defined as the fraction of phenotypic varia-
tion that can be attributed to a genetic origin. Twin cohort 
microbiome studies utilizing monozygotic and dizygotic 
twin cohorts indicate that host genetics control the makeup 
of the gut microbiome, and that colonization by discrete taxa 
is highly heritable (Goodrich et al. 2016, 2014; Lim et al. 
2017; Turnbaugh et al. 2009; Xie et al. 2016). In a 2014 
study of 416 twin pairs, Goodrich et al. (Goodrich et al. 
2014) showed using the classic 16S rRNA gene-sequencing 
approach, in which a region of the 16S rRNA is amplified, 
sequenced, and compared to databases for taxonomic assign-
ment that 5.3% of the taxa had a heritability greater than 
20% (Xie et al. 2016). In 2017, Lim et al. (Lim et al. 2017) 
showed using the same approach that among 85 taxa, more 
than half were significantly heritable with heritability rang-
ing between 13.1 and 45.7%, depending on the microbe. 
A single twin study utilizing a whole-genome shotgun-
sequencing approach (Xie et al. 2016) showed strong her-
itabilities for Dorea (42.2%) and Bifidobacterium (30.9%) 
abundance. These significant heritability estimates demon-
strate that microbial abundance is amenable to genetic map-
ping as a complex trait.
Twin studies identify genomic loci associated 
with microbial abundance in humans
The twin studies described above were powered well enough 
to not only calculate heritability for microbial abundance but 
also identify genomic regions associated with the abundance 
of specific microbes (Table 1). The most significant findings 
from the Goodrich studies (Goodrich et al. 2016, 2014) were 
the association of a SNP (rs2164210) in the lactase gene 
(LCT) with the abundance of Bifidobacterium (p < 0.001) 
and a SNP (rs2276731) in the gene for an aldehyde dehy-
drogenase family member (ALDH1L1) with the abundance 
of unclassified SHA-98 bacteria (p < 0.001). In another twin 
study, a SNP (rs651821) in the apolipoprotein A5 (APOA5) 
gene was associated with the abundance of Bifidobacterium 
in patients with metabolic syndrome (Lim et al. 2017). Twin 
studies used to calculate the heritability of a trait are most 
useful for microbiome traits as vertical transmission (mother 
to offspring) is controlled for in these studies. These twin 
studies show that specific genomic loci that function in regu-
lating the abundance of discrete gut microbes can be identi-
fied by utilizing cohorts of monozygotic vs dizygotic twins 
to disentangle the shared genetic and environmental factors.
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Table 1  Human loci associated with microbial abundance
Approach Chromosome SNP Gene Microbe Target Sample
size
Reference
Twin Studies 11 rs651821 APOA5 Bifidobacterium 16S V4 655 (Lim et al. 2017)
Twin Studies 3 rs2276731 ALDH1L1 Unclassified SHA‐98 16S V4 1126 (Xie et al. 2016)
2 rs6730157 RAB3GAP1 Bifidobacterium
2 rs2164210 LCT Bifidobacteria
7 rs1360741 CD36 Blautia
11 rs1506977 OR6A2 Cc 115 (family
Erysipelotrichaceae)
7 rs1182182 GNA12 SMB53 (family
Clostridiaceae)
11 rs1506977 rs1506977 Cc 115 (family
Erysipelotrichaceae)











16S V1‐V9 178 (Frank et al. 2011)







19 rs601338 FUT2 Alistipes, unclassified 
Lachnospiraceae, 
and Coprococcus

















NOD2 Enterobacteriaceae 16S V4 474 (Knights et al. 
2014)
GWAS 3 rs4894707 PLD1 Akkermansia 16S V4 114 (Davenport et al. 
2015)
GWAS 2 rs56064699 LCT Bifidobacterium 16S V3‐5 93 (Blekhman et al. 
2015)
2 rs1050115 UBXN4 Bifidobacterium
3 rs1110168 PLXND1 Prevotella
11 rs1966834 OR1S1 Prevotella
14 rs8019270 TBPL2 Prevotella
20 rs2274669 PCED1A Alistipes
7 rs10248138 EPDR1 Lachnobacterium
GWAS 1 rs12137699 VANGL1 Family Sutterellaceae WGS 1514 (Bonder et al. 
2016)
2 rs7605872 Species Dialister 
invisus
6 rs4548017 Class Methanobacteria
9 rs1081306616 LINGO2 Genus Blautia
10 rs1889714 Species Dialister 
invisus
11 rs16913594 Species Bacteroides 
xylanisolvens
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Table 1  (continued)












2 rs62171178 UBR3 Rikenellaceae (Turpin et al. 
2016)
3 rs1394174 CNTN6 Faecalibacterium
1 rs59846192 DMRTB1 Lachnospira
18 rs28473221 SALL3 Eubacterium







1 rs6666120 ACTL8 Methanobrevibacter
GWAS (followed 
TWIN)
3 rs7433197 FHIT Clostridiales (OTU
181,702)
16S V4 3666 (Beaumont et al
2016; Le Roy 
et al. 2018)
6 rs1433723 TDRG1 Clostridiales (OTU
25,576)
1 rs2480677 ELAVL4 Blautia (OTU 194,733)
GWAS 1 rs938295 FBLIM1 Unclassified
Enterobacteriaceae
16S V1‐V2 1812 (Wang et al. 2016)
1 rs75036654 LINC01137 Unclassified
Acidaminococcaceae






2 rs79387448 SLC9A2 Blautia genus







2 rs56006724 C2orf83 Unclassified
Acidaminococcaceae
3 rs11915634 CNTN6 Marinilabiliaceae 
family/Unclassified 
Marinilabiliaceae




3 rs13096731 FLNB Escherichia Shigella
3 rs59042687 LINC00879 Lactobacillales order
3 rs9831278 LINC00973 Unclassified
Marinilabiliaceae
3 rs62295801 LINC01192 Lactobacillales order
3 rs7646786 LOC344887 Bacilli class
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Table 1  (continued)
Approach Chromosome SNP Gene Microbe Target Sample
size
Reference
4 rs7656342 DRD5 Unclassified
Porphyromonadaceae






5 rs9291879 CD180 Unclassified
Porphyromonadaceae
5 rs249733 SPRY4 OTU10032 unclas-
sified
Enterobacteriaceae
7 rs17661843 ABCA13 Unclassified
Acidaminococcaceae
8 rs13276516 TGS1 OTU10032 unclas-
sified
Enterobacteriaceae














12 rs479105 PRMT8 Bacilli class




13 rs9300430 RAP2A Gammaproteobacteria 
class
14 rs9323326 SLC35F4 Proteobacteria phylum
14 rs986417 SIX6 Unclassified
Acidaminococcaceae
14 rs11626933 C14orf102 Unclassified
Erysipelotrichaceae
15 rs12442649 TMCO5A OTU15355 Dialister
Species‐level OTU
15 rs35275482 BNIP2 Enterobacteriaceae 
family
16 rs12149695 FLJ21408 OTU10032 unclas-
sified
Enterobacteriaceae
16 rs1362404 TOX3 Lactobacillales order
18 rs11877825 NAPG Erysipelotrichaceae 
family
19 rs148330122 SIPA1L3 Bacilli class
20 rs2071199 HNF4A‐AS1 Bacilli class
21 rs34613612 KRTAP8‐1 Actinobacteria class
GWAS 9 rs150018970 RAPGEF1 Ruminococcus 16S V4 3890 (Hughes et al. 
2020)
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Table 1  (continued)




16 rs55808472 ARHGAP17 Butyricicoccus
11 rs4494297 EXT2 Sutterellaceae
11 rs7118902 SORl1 Dialister
13 rs35980751 ABCC4 Porphyromonadaceae
6 rs13207588 FOXP4 Parabacteroides
2 rs6733298 CCDC85A Erysipelotrichaceae
15 rs116865000 Gammaproteobacteria
9 rs11788336 IKBKAP Firmicutes
6 rs34656657 ATXN1 Firmicutes
4 rs116135844 SPOK3 Bacteroidales
15 rs117338748 LIPC Veillonella
GWAS 16 rs3803713 HS3ST4 Faecalibacterium 16S V3‐V4 1,068 (Ishida et al. 
2020)
21 rs2839417 C2CD2 Erysipelotrichaceae
2 rs6545786 2p16.1 Prevotella
10 rs1033781 10p15.1 Oscillospira
18 rs885034 18q12.2 Alpha diversity index
GWAS rs182549 LCT Bifidobacterium 16S Various 18,340 (Kurilshikov et al. 
2021)
3 rs9864379 Gastranaerophilales V4, V3‐V4, 
V1‐V2
3 rs75754569 IRF1 Peptococcus
3 rs4428215 FNDC3B Oxalobacteraceae
4 rs10805326 Intestinibacter
4 rs11098863 Enterorhabdus
7 rs10805326 Eubacterium copros-
tanoligenes

















19 rs35866622 FUT2‐FUT1 Ruminococcus torques
270 J. A. Bubier et al.
1 3
Human genetic association studies or candidate 
gene studies have associated human genomic 
regions with microbial abundance
Another approach to determining genomic linkage is 
through genetic association studies, which test for cor-
relations between altered phenotype and regional genetic 
variation to identify genomic loci that contribute to the 
altered phenotype. Genetic association studies have iden-
tified several specific relationships between host genetics 
and microbiome composition (Table 1). The human major 
histocompatibility complex, specifically the DRB1 haplo-
type, a rheumatoid arthritis risk locus, is correlated with 
Prevotella copri expansion (p < 0.001) (Scher et al. 2013) 
in untreated new-onset rheumatoid arthritis, but once 
treated, Prevotella copri abundance in chronic patients is 
not different from healthy controls. The fucosyltransferase 
2 (FUT2) gene (Rausch et al. 2011; Wacklin et al. 2011), 
nucleotide-binding oligomerization domain containing 2 
(NOD2) gene, and autophagy-related 16 like 1 (ATG16L1) 
(Frank et al. 2011) were also associated with microbial 
abundance using genotype association studies.
Human genome‑wide association studies have 
associated numerous loci with microbial abundance
Genome-wide association studies (GWAS) utilize the 
approach of genotype association studies but use large 
sample sizes and unbiased markers throughout the genome 
to link genotype to phenotype rather than testing the asso-
ciation of a phenotype with only a specific individual gene 
or genomic region as in genetic association studies. GWAS 
can link specific SNPs to a phenotype of interest, such 
as the composition and abundance of specific microbes 
within the microbiome. They are superior to twin studies 
as you are not limited to collecting data from just monozy-
gotic and dizygotic twin samples which makes it difficult 
to reach large sample sizes and the power to detect traits 
with lower heritabilities. The linked SNP in GWAS may be 
in a gene or be associated with the nearest gene or genomic 
feature by convention. As shown in Table 1, GWAS have 
enabled the detection of numerous SNPs associated with 
the abundance of specific microbes. Like the twin studies 
(Xie et al. 2016), GWAS identified LCT in association 
with Bifidobacterium (Blekhman et al. 2015). One GWAS 
confirmed the association of SNPs in ubiquitin-protein 
ligase E3 component n-recognin 3 (UBR3) gene, contactin 
6 (CNTN6) gene, DMRT like family B with proline-rich 
C-terminal 1(DMRTB1) gene, and spalt-like transcription 
factor 3 (SALL3) gene that was associated with the abun-
dances of Rikenellaceae, Faecalibacterium, Lachnospira, 
and Eubacterium, respectively (Turpin et al. 2016) in mul-
tiple independent cohorts. The most GWAS hits reported 
to date were found in a study by Wang et al. (Wang et al. 
2016) in which 40 different loci were significantly associ-
ated with microbial abundance at a variety of levels (class, 
order, family, or genus) in two cohorts from northern Ger-
many totaling 1812 individuals. Thus far, only one GWAS 
study used whole-genome shotgun sequencing rather than 
16S sequencing to inventory the microbiome composition 
(Bonder et al. 2016). In this study of 1514 individuals, 
nine genetic loci were associated with specific microbes 
classified at levels ranging from the family to the species 
level. A recent GWAS study utilizing numerous popula-
tions and microbiome sequencing methods identified 20 
loci and reproduced the LCT association with Bifidobac-
terium (Kurilshikov et al. 2021). Overall, twin studies, 
genetic association studies, and GWAS have identified at 
least 110 different loci associated with the abundance of 
specific gut microbes.
The GWAS and genetic association studies approach to 
calculating heritability in microbiome-related traits must be 
interpreted with caution (Tam et al. 2019). In these stud-
ies, vertical transmission from mother to offspring is not 
controlled for, unlike in twin studies, and the mode of child 
delivery also affects the microbiome (Dominguez-Bello 
et al. 2010). In addition, large, population-based studies such 
as these do not account for diet or environment, two of the 
strongest drivers of microbiome composition (Dominguez-
Bello et al. 2010; Rothschild et al. 2018). In GWAS, the 
population size and significance level needed to correct for 
genome-wide multiple testing and for traits of low herit-
ability that remain under consideration (Dudbridge and 
Gusnanto 2008). GWAS studies only explain a proportion 
of the heritability, with other factors such as epistatic and 
gene-environment interactions not captured (Manolio et al. 
2009). Finally, associations between host gene and bacte-
rial abundance do not often replicate across GWAS stud-
ies, likely due to variation in diet, environment, and specific 
population studied.
Genetic analysis identifies loci associated 
with microbial abundance in mice
Microbiome studies in laboratory mice allow for the control 
of many variables within an experiment that are not control-
lable in human studies. Laboratory mice are an important 
model system for microbiome studies due to the ability to 
produce germ-free (GF) or microbiome-depleted animals 
and introduce microbiomes by FMT or by manipulating the 
microbiome by other methods such as treatment with antibi-
otics or altering the diet. This type of control is essential as 
the environment, and diet has been shown to have the most 
substantial effect on the microbiome (Dong and Gupta 2019; 
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Rothschild et al. 2018). When mice are provided a defined 
environment controlling for location, room, diet, and cage 
effect within a study, host genetics accounts for a large pro-
portion of remaining microbial variation. The genetic effect 
on the microbiome is illustrated by the intrinsic difference 
in microbiome between inbred strains of mice (Benson et al. 
2010; Campbell et al. 2012; Leamy et al. 2014; McKnite 
et al. 2012; Org et al. 2015). The combination of variation 
in the microbiome by strain and the powerful tools of mouse 
genetics offer a highly effective approach for studying the 
genetic control of the microbiome.
Quantitative trait loci (QTL) mapping in genetically 
diverse mice has enabled the identification of genomic 
regions associated with the microbiome (Table 2, Supple-
mentary Table 1). The first mouse microbial abundance QTL 
studies, performed in generation four of a C57BL/6 J x ICR 
advanced-intercross line (AIL) (Benson et al. 2010) using 
V1-V2 16S sequence from fecal pellets, identified 18 sig-
nificant or suggestive host QTL, with each QTL accounting 
for 1.6–9.0% of the variation in microbe abundance. AILs 
accumulate additional crossovers with every successive gen-
eration, leading to a population with smaller linkage disequi-
librium (LD) blocks. The original study was followed up 
four years later using the  10th generation intercross of these 
mice. This mapping cross identified 42 QTL. Each of the 
identified QTL explains an average variance of 4.64% of a 
particular microbe’s microbial abundance. Additional stud-
ies have been performed through the years, all utilizing 16S 
sequencing for microbiome composition in various mouse 
populations such as the BXD Recombinant Inbred Panel 
(McKnite et al. 2012; Perez-Munoz et al. 2019), Collabora-
tive Cross (Bubier et al. 2020; Snijders et al. 2016), Hybrid 
Mouse Diversity Panel (Org et al. 2015; van Opstal and Bor-
denstein 2015), and Diversity Outbred (DO) mice (Kemis 
et al. 2019). These studies have contributed an additional 
348 loci associated with microbial abundance (Supplemen-
tary Table 1). Particularly for mice, there have been few 
occurrences of the same locus being found in multiple stud-
ies. Some of this ‘failure to replicate’ can be attributed not 
only to the differential diets, husbandry practices, and health 
status found across studies and facilities, but also to the fact 
that the same genetic polymorphisms are not present in the 
same populations and would, thus, not be expected to rep-
licate. For example, there will be loci detected in the BXD 
RI population that will not be detected in the DO because 
of the lack of DBA2-specific polymorphisms in the latter 
population. Taken together, the discovery of so many loci 
suggests that there are many genes involved in the control 
of the microbiome, but the inability to replicate genetic loci 
across studies indicates the importance of testing the causa-
tive loci using genetic knock-out experiments.
Gene knock‑out studies validate host genes 
controlling microbiome abundance
A common approach to verifying the involvement of a gene in 
a process is to inactivate the gene of interest through genetic 
engineering and define the effect on phenotype. As it relates 
Table 2  Mouse microbial QTL mapping studies
Publication # Strains Population Number of Loci Statistical criteria Source Target
(Benson et al. 2010) 645 animals G4 AIL (B6J x ICR) 18 Significant or sug-
gestive
Fecal pellets 16S V1‐2
(Hillhouse et al. 
2011)
314 animals F2 (B6 x AJ) 10 Significant Cecal contents Helicobacter
(McKnite et al. 2012) 61 animals (30 
Strains)
RI (BXD) 9 Significant Fecal pellets 16S V1‐2
(Leamy et al. 2014) 472 animals G10 AIL (B6J x ICR) 42 1 significant post 
FDR
Fecal pellets 16S V1‐2
(Org et al. 2015) 599 (110 Strains) HDMP 7 Significant Cecal contents 16S V4
(Wang et al. 2015) 334 animals F2( WSB/EiJ x 
PWH/PhJ)
20 Significant Cecal contents 16S V1‐2
(Snijders et al. 2016) 293 animals (30 
Strains)
RI (CC) 169  − log10(P value) > 6) Fecal pellets 16S V4
(Kemis et al. 2019) 500 animals Outbred (DO) 28 4 Significant Fecal pellets 16S V4
(Perez‐Munoz et al. 
2019)
 ~ 128 animals (32 
Strains)
RI (BXD) 27 Significant Cecal contents 16S V5‐V6




(Bubier et al. 2020) 201 animals (108 
Strains)
RI (pre‐CC) 18 Significant post FDR Cecal contents 16S V1‐2, V4
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Tlr5 1 The gut microbiotica shows enrichment or reduction of 116 bacterial phylotypes relative 
to wild-type controls and transplanting gut microbiota from homozygotes to germ-free 
control hosts confers many aspects of the metabolic disease phenotype
(Chassaing et al. 2014); 
(Vijay-Kumar et al. 
2010)
Card9 2 The LEfSe analysis revealed differences including decreases in Adlercreutzia (genus), 
Actinobacteria (phylum), and Lactobacillus reuter in the Card9 − / − mouse microbiota. 
Mice fail to metabolize tryptophan into metabolites that act as aryl hydrocarbon recep-
tor (AHR) ligands
(Lamas et al. 2016)
Pglyrp3 3 Have reduced Lactobacillus/Lactococcus, Enterobacteriaceae, and Eubacterium 
rectale/Clostridium coccoides, and Clostridium perfringen groups
(Saha et al. 2010)
Pglyrp4 3 Have reduced Lactobacillus/Lactococcus and segmented filamentous bacteria groups 
increased Bacteroides group
(Saha et al. 2010)
Tlr2 3 Display a threefold increase in Firmicutes and a slight increase in Bacteroidetes com-
pared with controls
(Caricilli et al. 2011)
Lepr 4 Have a significant higher abundance of Firmicutes, Proteobacteria, and Fibrobacteres 
phyla in db/db mice compared to lean mice
(Geurts et al. 2011)
Ptpn11 5 Have an increase in Enterobacteriaceae and a decrease in Firmicutes were observed in 
the colon of these mice
(Coulombe et al. 2016)
Aicda 6 Mice exhibit an increase in bacteria, especially anaerobic bacteria, in the small intestine 
compared with wild-type mice. Some mice exhibit an expansion of unclassified Lach-
nospiraceae of the order Clostridiales while others exhibit increased Bacteroidales or 
Lactobacillus compared with wild-type mice
(Wei et al. 2011)
Reg3g 6 Mice exhibit a higher mucosal bacterial loads (gram-positive Firmicutes phylum [Lac-
tobacillus, Eubacterium rectale, and segmented filamentous bacteria (SFB) groups]) 
compared with wild-type mice; however, luminal bacterial loads are normal
(Vaishnava et al. 2011)
Lep 6 ob/ob animals have a 50% reduction in the abundance of Bacteroidetes and a propor-
tional increase in Firmicutes
(Ley et al. 2005)
Nlrp2 7 Dysbiosis marked by increased obesity-associated Erysipelotrichaceae but reduced 
Lachnospiraceae family and the associated enzymes r
(Truax et al. 2018)
Nlrp6 7 Mice and co-housed wild-type mice exhibit expanded bacterial phylotypes compared 
with wild-type mice
(Elinav et al. 2011)
Pglyrp1 7 Have reduced segmented filamentous bacteria (Saha et al. 2010)
Fut2 7 Salmonella typhimurium susceptibility (Goto et al. 2014)
Nod2 8 Relative abundances of several clostridial genera were associated with disease pheno-
type, NOD2 composite genotype, and/or ATG16L1genotype
(Frank et al. 2011;
Rehman et al. 2011)
Myd88 9 Increased abundances of Lactobacillaceae, Rikenellaceae, and Porphyromonadaceae 
phylotype
(Wen et al. 2008)
Apoa1 9 12% variation of a Partial Least-Square Discriminate Analysis of microbiota structure 
accounted for by genotype
(Zhang et al. 2010)
Mmp7 9 Increased sensitivity to Salmonella typhimurium. KO mice also have increase Firmicutes 
(specifically Clostridia) an decreased Bacteroidete) compared to wild type
(Wilson et al. 1999),
(Salzman et al. 2010)
Atg5 10 Have a dramatically altered composition of the gut microbiota and reduced alpha diver-
sity. “Candidatus Arthromitus” and the Pasteurellaceae family were increased in KO 
mice, whereas Akkermansia muciniphila and the Lachnospiraceae family were reduced
(Yang et al. 2018)








Pik3cg 12 Between WT and KO 11 taxa were found to increase significantly and five taxa 
decreased significantly in KO mice compared to WT mice
(Li et al. 2020)
Igha 12 Mice deficient in IgA harbor an increased abundance of SFB (Suzuki et al. 2004)
Ccl28 13 The abundance of Class Bacilli bacteria is increased in the intestine (Matsuo et al. 2018)
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to microbial abundance, the knock-out (KO) of specific genes 
has been shown to produce distinct gut microbiomes or altered 
bacterial colonization engraftment compared to control mice 
in which the target gene is not inactivated. At least 30 genomic 
loci have been identified that, when deleted from the germline, 
result in altered microbiome composition, often in addition 
to other phenotypes (Table 3). For example, the absence of 
activation-induced cytidine deaminase (AID) results in the 
absence of hypermutated IgA. The lack of IgA in these mice 
makes them susceptible to predominant and persistent expan-
sion of segmented filamentous bacteria (SFB) (Suzuki et al. 
2004). In other examples, an intervention may be necessary 
to reveal an altered microbiome phenotype in KO mice. The 
altered microbiome composition of NLR family, pyrin domain 
containing 3 (Nlrp3) KO mice (Nlrp3tm1Bhk), is not as apparent 
until the mice are subjected to environmental manipulation, 
such as feeding the mice a Western lifestyle diet (Pieran-
tonelli et al. 2017), which exposes the microbiome differences 
between KO and control mice. The numerous mutations with 
effects on the microbiome demonstrate the variety of genes 
through which the host maintains the critical homeostatic 
regulation of the microbiota.
Conditional deletion of toll-like receptor 5 (Tlr5) from 
intestinal epithelial cells shows low-grade inflammation, 
metabolic syndrome, and colitis as compared to wild-type 
littermates (Chassaing et al. 2014). These conditional KO 
mice show enrichment or reduction of 116 bacterial phylo-
types relative to controls. Antibiotic treatment of the condi-
tional KO mice eliminates the inflammation and associated 
metabolic syndrome (Chassaing et al. 2014). Transplanting 
gut microbiota from homozygote conditional KO mice to 
germ-free control hosts confers many aspects of the meta-
bolic disease phenotype on those mice (Vijay-Kumar et al. 
2010). These studies specifically showcase the importance 
of intestinal Tlr5 in the maintenance of the gut microbiome.
Another approach using genetically engineered mice to 
dissect host control of the microbiome has been to produce 
mice that express human genes from a transgene. To under-
stand the role of antimicrobial peptides in microbiome com-
position, the human alpha-defensin (DEFA5) gene, a com-
ponent of enteric mucosal innate immunity, was introduced 
into FVB mice (Salzman et al. 2010). The transgenic expres-
sion of DEFA5 resulted in mice with a decreased proportion 
of Firmicutes and decreased SFB colonization compared to 
non-transgenic control FVB mice. This manipulation sug-
gests that alpha-defensins play an essential role in regulating 
the makeup of the commensal microbiota. The creation of 
genetically identical mouse strains that differ in the pres-
ence of one gene and that display significant differences in 
microbiome composition supports the concept that the host 




Sugct 13 Mice show differences in the proportion of and type of bacteria species in stool, with 
an increase of firmicutes relative to Bacteroidetes (strongest in Blautia genus contain-
ing the families Ruminococcaceae and Lachnospiraceae, then Adlercreutzia genus, 
Bilophilia genus, and AF12 genus and a decrease in Bifidobacterium genus); microbi-




Olfm4 14 Following oral challenge, mice exhibit reduced colonization by Helicobacter pylori and 
increased infiltration of inflammatory cells in the gastric mucosa compared with wild-
type mice
(Liu et al. 2010)
Vdr 15 Lactobacillus was depleted in the fecal stool, whereas Clostridium and Bacteroides were 
enriched. Bacterial taxa along the Sphingobacteria-to-Sphingobacteriaceae lineage 
were enriched
(Jin et al. 2015)
Retnlb 16 Fifteen Bacteriodetes lineages, and 1 lineage of Proteobacteria, changed in abundance 
between genotypes, whereas 15 Firmicutes lineages changed in abundance
(Hildebrandt et al. 2009)
Percc1 17 Display an altered intestinal and fecal microbiome composition (Oz-Levi et al. 2019)
Pglyrp2 17 Have reduced Lactobacillus/Lactococcus, segmented filamentous bacteria, Clostridium 
perfringens, and Bacteroides groups
(Saha et al. 2010)
Npc1 18 The gut microbiota composition shifted and increased microbial richness and diversity 
Specifically, Staphylococcus spp. and unclassified Mogibacteriaceae spp. Mice showed 
significantly higher levels in relative abundance in the KO mice compared to WT mice, 





Tg Clostridium-like bacterium abundance altered (Gomez et al. 2012)
DEFA5 Tg Mice have a decreased proportion of bacteria from the Firmicutes, and decreased SFB (Salzman et al. 2010)
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genotype controls the microbiome and may subsequently 
affect disease phenotypes.
Cross‑species conservation of host genes 
that modulate the microbiome
Many confounding factors, especially diet and environment 
which are strong microbiome composition drivers, prevent 
replication across studies in humans and mice. Despite these 
challenges, some loci have demonstrated conserved function 
across species. For example, the genes NOD2 (Frank et al. 
2011; Knights et al. 2014; Rehman et al. 2011) and FUT2 
(Goto et al. 2014; Rausch et al. 2011) have been associated 
with microbiome composition in both species. NOD2 was 
identified in a human GWAS as a host gene associated with 
the microbiome composition and inflammatory bowel dis-
ease. This dysbiosis was recapitulated in KO mice revealing 
alteration in multiple distinct microbes associated with the 
disease phenotype. FUT2, the gene responsible for the ABO 
histo-blood group antigens, was associated in human stud-
ies with Crohn’s disease and altered microbial community 
composition. Fut2 knock-out mice result in altered epithe-
lial fucosylation and increased susceptibility to Salmonella 
typhimurium. These studies implicate conserved functions 
across species for NOD2 and FUT2 in modulating the gut 
microbiome.
Microbiome control of host gene expression
GF mice display an array of physiological and behavioral 
abnormalities (Clarke et al. 2013; Desbonnet et al. 2014; 
Diaz Heijtz et al. 2011; Neufeld et al. 2011). Because they 
lack a normal microbiota, the epithelial barrier function, 
gut homeostasis, and innate and adaptive immune functions 
of GF mice develop differently (Hooper and Gordon 2001; 
Lundin et al. 2008). These developmental differences result 
in altered hippocampal serotonergic signaling and altered 
expression of genes known to be involved in synaptic long-
term potentiation in the striatum (Clarke et al. 2013; Diaz 
Heijtz et al. 2011; van Opstal and Bordenstein 2015). As a 
result of neural differences, these mice are less anxious and 
display increased locomotor activity than specific pathogen-
free (SPF) control mice (Diaz Heijtz et al. 2011). The pres-
ence of an intact microbiome is, thus, an essential require-
ment for normal development.
Specific microbes have been found to regulate host gene 
expression. For example, in cultured human cells, lipopoly-
saccharide (LPS) from Escherichia coli and other proteobac-
teria caused an inflammatory response by activating toll-like 
receptor 4 (TLR4), leading to a gene expression cascade of 
innate immune pathways (Rallabhandi et al. 2008),. Micro-
array analysis in mice showed that ~ 700 host intestinal 
genes were differentially expressed between GF mice and 
SPF mice (Cresci et al. 2010; Liu et al. 2016), which are 
free of specific pathogens determined from routine testing 
but are not GF and, thus, harbor a microbiome. The latter 
showed that bacterial recolonization of the intestinal tract of 
GF mice reversed some of these gene expression changes. In 
a different experiment, FMT of germ-free C3H mice, which 
harbor a mutation in the Tlr4 gene, with C57BL/10 feces 
resulted in 202 genes differing more than twofold in expres-
sion (Brodziak et al. 2013). The behavioral abnormalities of 
GF mice related to anxiety were corrected when they were 
given an SPF microbiome (Cresci et al. 2010; Liu et al.). 
Similarly, in another mouse experiment, the depletion of the 
gut microbiome through antibiotic treatment caused cogni-
tive impairment, accompanied by changes in the expression 
of cognition-relevant signaling molecules in specific regions 
of the brain (Frohlich et al. 2016). These observations sup-
port a host–microbiome interaction model where the micro-
biome alone can independently modulate the expression of 
host genes and subsequently affect a phenotype.
There is growing evidence that the effects of the micro-
biome on host gene expression are modulated through the 
epigenome. The epigenome is the chemical modifications 
to DNA and histone proteins that regulate the expression of 
genes and is thought to be regulated in part by the metab-
olome (Krautkramer et al. 2017). The metabolome is the 
collection of metabolites produced during metabolism and 
includes those metabolites produced by the gut microbiome. 
Thus, the metabolome can be thought of as the functional 
intermediate between the microbiome and host gene expres-
sion (reviewed in (Krautkramer et al. 2021)). Short-chain 
fatty acids (SCFAs) produced by the microbiome regulate 
host defenses and the immune system through epigenetic 
control by inhibiting histone deacetylation. Butyrate, a 
known histone deacetylation inhibitor (Davie 2003; Wu et al. 
2020), produced by commensal microbes such as Clostridia 
has been shown to induce regulatory T cell development by 
enhancing histone H3 acetylation (Furusawa et al. 2013). 
The gut microbiome induces epigenetics changes of all 
types, DNA methylation, histone modification and regula-
tion by non-coding RNA to control gene expression of the 
host.
Opportunities and considerations in the use 
of animal models to study host genetic‑microbiome 
interactions
Animal studies allow researchers to have exquisite control 
over the environment of their animals. Each research loca-
tion determines what the SPF health status of their vivarium 
will be. The health status corresponds to which microbes 
are excluded, through routine testing, from being present 
within a mouse colony. This variation in SPF status across 
vivaria has inadvertently enabled researchers to determine 
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that the phenotype of some inbred strains of mice vary based 
upon the presence of specific microbes. One such example 
is diabetes, a condition that is present in NOD/ShiLtJt mice. 
In this well-characterized type 1 diabetes (T1D) model, dia-
betes develops in young (3–5 week-old) mice as autoreac-
tive T-cells destroy the insulin-producing beta cells in the 
pancreas. Researchers using this model in vivaria that screen 
for fewer pathogens (lower SPF status) noticed a decreased 
incidence of T1D in their NOD/ShiLtJt mice (Pozzilli et al. 
1993). This was due to the presence of segmented filamen-
tous bacteria class of microbiota in their facility. The seg-
mented filamentous bacteria class of microbiota is known 
to influence the severity of the autoimmune response by 
triggering a counter  Th17 immune response that decreases 
the autoreactivity and protects the mice from developing 
T1D (Ivanov et al. 2009). This same mouse model displayed 
decreased T1D when given acidified drinking water, which 
significantly altered the microbiome, specifically levels of 
Actinobacteria, Proteobacteria, and Firmicutes, similarly 
decreasing the  Th17 mediated autoreactivity (Wolf et al. 
2014). Thus, the control researchers have over the environ-
ment of animals that has provided various, sometimes unex-
pected insights.
A recent commentary emphasizes the importance of 
“Knowing your model and its microbiota” (Perry et  al. 
2020). The example that best exemplifies this thesis is the 
finding that the gut microbiome is causative for a phenotypic 
change of a mutant transformation-related protein 53 (Trp53) 
to switch from tumor suppressor to oncogene in the context 
of a genetic model for intestinal cancer (Csnk1a1tm1.1Ybn) 
(Kadosh et al. 2020). This change was due to the presence 
of a microbiome-derived metabolite, gallic acid, which abol-
ishes the tumor-suppressive nature of the mutation only in 
a region of the distal gut where the gallic acid-producing 
microbe is present. This is an example of an interaction 
between host genotype (mutant Trp53) and microbiome 
(gallic acid-producing microbe) that creates an altered phe-
notype (malignancy). Taken together, a comprehensive view 
that includes both host genetics and microbiome composi-
tion is critical to fully understand the relationship between 
genes and the manifestation of the disease (van Opstal and 
Bordenstein 2015).
Experiments to dissect the cause‑and‑effect 
relationships of the host and microbiome
A major challenge for understanding host–microbiome inter-
actions is determining causality of an altered phenotype due 
to a genetic alteration. As illustrated in Fig. 1, variation in 
the host genome can alter a phenotype in multiple ways. 
The ability to transfer a specific phenotype from donor to 
recipients in FMT experiments is one way to distinguish 
between the altered microbiome being causative of the 
disease phenotype or the altered microbiome being a subse-
quent manifestation of the disease processes. One example 
is the case of the NOD2 gene, which is associated with both 
IBD and an altered microbiome (Frank et al. 2011; Rehman 
et al. 2011). Wild-type mice were transplanted with fecal 
material from the NOD2 knock-out mouse, and the recipi-
ent mice developed features of IBD seen in the NOD2 fecal 
donor mice (Couturier-Maillard et al. 2013). The transfer 
of disease phenotype by the transfer of the microbiome 
suggests that the genetic variant alters the microbiome 
directly, which results in an altered phenotype (Fig. 1, Path-
way III). Similarly, we tested causality using the BKS.Cg-
Dock7m + / +  Leprdb/J mouse, a model of leptin deficiency, 
resulting in obesity, type-2 diabetes, and abnormal sleep pat-
terns in the form of altered sleep–wake regulation (Laposky 
et al. 2008). This strain possesses various microbes that are 
absent in their wild-type littermates (Geurts et al. 2011). 
We found that treatment of these mice with antibiotics 
resulted in the restoration of sleep behaviors, suggesting 
that the genetic variant altered the microbiome, which was 
responsible for the phenotype (Fig. 1, Pathway III). Addi-
tional experimentation is needed to identify the microbe or 
metabolites involved and the mechanisms through which the 
microbiome controls sleep behavior. These studies highlight 
how FMT can be used to define cause-and-effect relation-
ships between microbiome composition and host phenotype.
APP/PS1transgenic mice (Tg), a well-established neuro-
degenerative model of Alzheimer’s disease, are associated 
with microbiome shifts over time (Bauerl et al. 2018). The 
microbiomes of wild-type versus. Tg mice begin to diverge 
at six months of age, with the Tg mice having an increase 
in the genus Sutterella which is concurrent with the time 
when the animals develop β-amyloid deposits in the brain. 
By 24 months of age, the microbiome of the Tg mice is 
enriched with Erysipelotrichaceae, a known inflammation-
related microbe. In this case, it is not yet clear what the 
status of causality is (Fig. 1, Pathways I, II, or III). Experi-
mental observations such as these make causal experimen-
tation such as FMT a priori to determine to what extent the 
AD-associated changes accelerate the AD pathology, and if 
so, whether microbiome-mediated interventions might alter 
AD pathology.
Important next steps and priorities
The human and mouse microbiomes have been described 
as qualitatively alike but quantitatively different (Krych 
et al. 2013) in that they each include a qualitatively simi-
lar core of specific phyla but the abundance of specific 
phyla and species differ. In contrast to the microbiome, 
the DNA sequence in the protein-coding regions of the 
mouse and human genomes is 85% identical (Mouse 
Genome Sequencing et al. 2002). Because of this genomic 
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conservation, the mouse has an extensive history of being 
used for understanding the genetics of human health and 
disease (Hedrich 2012); with emerging populations captur-
ing the genetic diversity equivalent to what is seen in the 
human population (Saul et al. 2019). The mouse microbi-
ome can be studied in these diverse mouse populations in a 
controlled laboratory environment, enabling the detection 
of loci involved in microbial abundance. Modern genomic 
engineering techniques such as CRISPR/Cas9 make the 
production of genetic knock-out mice and transgenic mice, 
a routine procedure. Once loci are identified, they can be 
validated using these mouse genetic engineering tech-
niques to determine causality.
In order to take the next step and perform necessary 
causal experimentation, additional resources are needed, 
and technological barriers need to be addressed. A key lim-
itation to understanding the microbiome of mice through 
16S sequencing is the lack of diversity of sequenced micro-
biomes in the reference database. Much of the 16S refer-
ence database sequence comes from human samples which 
have a different microbiome composition than mice. The 
C57BL/6 J and Lepob microbiomes have been characterized 
by two groups (Liu et al. 2020; Suez et al. 2014), producing 
reference WGS or 16S data as well as creating a biobank of 
126 species, represented by 244 bacterial strains. This effort 
included 77 new species being identified. Other groups have 
addressed microbiome diversity by cataloging the micro-
biome of six different inbred strains of mice from various 
institutions that were fed a variety of different diets (Xiao 
et al. 2015), thereby producing additional mouse-centric 16S 
data for the databases. The German Mouse Intestinal Bac-
terial Collection has sequenced the 16S of microbes from 
wild mice (Lagkouvardos et al. 2016), and made 104 cultural 
bacterial strains available on their website (www. dsmz. de/ 
miBC). We are currently working with the Diversity Outbred 
(J:DO) mouse population (Svenson et al. 2012) and routinely 
find that 30–50% of our 16S sequences are not in databases 
and/or represent new taxa that have not been phylogeneti-
cally placed and, thus, are not classified. 16S sequencing has 
inherent limitations due to copy number variation, as well as 
not being ideal to detect some microbial groups. As the field 
is adopting whole-genome sequencing in place of 16S analy-
sis, we have undertaken whole-genome shotgun-sequencing 
on a subset of mouse samples from a DO cohort and have 
assembled over 500 new genomes (unpublished). Other 
recent studies have produced larger sets of new genomes 
from mouse microbiomes (Lagkouvardos et al. 2016; Liu 
et al. 2020; Suez et al. 2014; Xiao et al. 2015).
Cataloging the existence of microbes is only step one. 
Having the microbes isolated to perform inoculation stud-
ies in vivo is an ideal intervention for causality studies. 
One challenge to this approach is the fact that numerous 
microbes are not able to be cultured in the laboratory. For 
other microbes, the strains available at microbial stock cent-
ers (such as the American Type Culture Collection) may not 
be the same as the commensal that are found in the mouse 
gut. One way that unculturable microbes can be studied is as 
part of the microbial ecosystem through fecal microbiome 
transplantations. Other approaches to address the uncul-
turable bacteria include antibiotic ablations or metabolite 
identification studies. The identification of the metabolites 
causing the phenotypes circumvents the need to culture the 
microbes all together.
The host genetic control of the microbiome is not just 
limited to the taxonomic level but also at the taxa-independ-
ent metabolite level. Some metabolites are made solely by 
microbes (e.g., butyrate), and others that are made by the 
host can also be made by microbes (e.g., serotonin). Instead 
of adding the microbe back, the microbiome can be removed, 
or the metabolic product of the microbe added back to the 
mice. A single microbe may not be responsible for a pheno-
type; rather, it may be caused by a group of microbes, some 
of which are depleted and others overabundant in causing a 
specific biological trait. Ultimately the microbiome is easier 
to manipulate (e.g., antibiotics, probiotics, prebiotics) than 
genome manipulation, and metabolic supplementation is 
even easier for the treatment of disease. These developments 
open the door to new therapeutic and diagnostic approaches.
Conclusions
The past two decades have produced many clues as to how 
the gut microbiome composition is affected by host genetics. 
These have come from the human twins, genetic association 
studies and GWAS, and numerous mouse QTL and gene 
knock-out studies; however, our overall understanding of the 
role of the host in the regulation of microbiome composition 
is in its infancy. While this review focuses on the genetics 
of the host, the diet and environment of the host are well-
known sources of variation of microbiome composition. The 
superb control of the genetics and environment of laboratory 
animals within an experiment enables scientists to untangle 
this mystery. Through the successful design and execution 
of causal experiments using a controlled intervention such 
as a genetic knock-out, FMT, specific microbial inocula-
tion, germ-free host, or antibiotic ablation, we will more 
fully understand the mechanisms controlling the diversity 
and composition of our bacterial symbionts and commen-
sals. As more mechanisms of host–microbial interactions 
and the causal relations of microbes and their metabolites 
to disease become better understood, the development of 
advanced therapeutic approaches informed by the microbi-
ome becomes a reality.
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